Zelmac Approved for Chronic Idiopathic Constipation by KFDA

Published: 2005-03-03 06:59:00

Updated: 2005-03-03 06:59:00

Novartis Korea announced on February 28th that the Korea Food and Drug Administration (KFDA) gave approval for a supplemental indication for its pro-motility drug Zelmac (active ingredient: tegaserod) for the treatment of chronic idiopathic constipation in male and female patients less than 65 ye...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK